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Management of castration-resistant prostate cancer (CRPC) is a major challenge in the clinic. Although CRPC treatment efficacy has been improved by using more powerful drugs targeting the androgen receptor-signaling axis, patient survival has only marginally increased and further improved versions of such drugs can lead to transdifferentiation of CRPC to currently incurable neuroendocrine prostate cancer. Therefore, new strategies targeting alternative, fundamental cancer properties are critically needed. Increasing evidence indicates that reprogrammed energy metabolism of cancers offers a unique target. For glucose utilization, cancer cells generally prefer glycolysis coupled to lactic acid production, i.e. aerobic glycolysis. This pathway leads to increased lactic acid secretion by cancers facilitating oncogenic processes, including tissue invasion/metastasis and neo-angiogenesis. The lactic acid secretion is predominantly mediated by MCT4, a plasma membrane transporter protein. Here 
we have

Introduction
Prostate cancer is the most commonly diagnosed non-cutaneous cancer and a leading cause of cancer death for North American men (1) . When the malignancy is confined to the prostate, surgery and radiation therapy can be curative. However, many treated patients experience local cancer recurrence and metastasis (2) . While androgen deprivation therapy (ADT), currently the treatment of choice for metastatic prostate cancer, can lead to remissions, tumours frequently return in a form that is highly resistant to ADT and other therapies, i.e. metastatic castration-resistant prostate cancer (mCRPC).
Although the efficacy of mCRPC treatment has recently been improved by using more powerful chemotherapeutics targeting the androgen receptor (AR)-signaling axis, such as enzalutamide (3) and abiraterone (4), the overall survival of patients has only marginally increased (5) (6) (7) . Moreover, it is thought that further improved versions of such drugs can promote transdifferentiation of prostatic adenocarcinoma to neuroendocrine prostate cancer (NEPC), a subtype of the disease that is currently incurable (8) (9) (10) . There is therefore a critical need for new, more effective strategies for therapy of CRPC that target different key properties of cancer.
There is increasing evidence that targeting reprogrammed energy metabolism of cancers offers a unique approach for effective therapeutic intervention (11) . For glucose utilization, cancer cells, as distinct from normal resting cells, in general have a preference for glycolysis coupled to lactic acid production, i.e. a process called aerobic glycolysis (the Warburg effect) (12) . This leads to elevated glucose consumption, a near-universal property of primary and metastatic cancers. In addition, aberrant utilization of glutamine, also leading to elevated lactic acid production, has been observed to be highly common for cancers (13) . These metabolic energy pathways lead to increased lactic acid secretion by the cancer cells into their microenvironment, facilitating multiple oncogenic, lactate-stimulated processes, including tissue invasion/metastasis, neo-angiogenesis and responses to hypoxia (14) (15) (16) (17) ; furthermore, lactic acid- Author Manuscript Published OnlineFirst on January 11, 2016; DOI: 10.1158/1078-0432.CCR- induced acidification of the cancer cell microenvironment (to pH 6.0-6.5) can lead to suppression of local host anticancer immunity (14, 18) . The phenomenon of enhanced glucose metabolism by cancers is most commonly exploited clinically by 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET).
Although this imaging technique is not generally used for prostate cancer (19) , there is evidence suggesting that glucose metabolism of prostate cancer cells is increased by AR signaling and progression to treatment resistance (20, 21) . As such, targeting the aerobic glycolytic pathway could be effective for treating advanced prostate cancers.
The monocarboxylate transporter (MCT) family consists of plasma membrane transporter proteins involved in the transport of lactic acid and other metabolic monocarboxylates. In particular, the cellular efflux of lactic acid/H + is thought to be predominantly mediated by MCT4 (SLC16A3) (22). Expression of MCT4 has been associated with highly glycolytic cells (17, 23, 24) , and elevated expression of MCT4 in tumours is clinically relevant as it has been associated with poor patient prognosis in multiple types of cancer (25) (26) (27) , including prostate cancer (28, 29). Furthermore, elevated MCT4 expression may be important in cancer-stroma interactions facilitating prostate cancer progression (30) . This information, together with the cancer growth-promoting ability of cancer-generated lactic acid, suggests that inhibition of the expression or function of MCTs provides a promising therapeutic strategy for a wide variety of neoplasms (31) . Currently, small molecule inhibitors of MCTs are available that specifically target MCT1 and MCT2 (e.g., AZD3965, AR-C155858) (32, 33) , non-specifically inhibit MCTs, including MCT1 and MCT4 (e.g., alpha-cyano-4-hydroxycinnamate) (34, 35) , or selectively inhibit lactic acid import via MCT4 (e.g., 7-aminocarboxycoumarins) (36) . However, a therapeutic strategy specifically targeting MCT4-mediated efflux of lactic acid is still lacking.
In the present study, we established that development of human CRPC is associated with elevated expression of MCT4. Furthermore, evidence was obtained that MCT4-targeting anti-sense 
Materials and Methods
Materials
Chemicals, solvents and solutions were obtained from Sigma-Aldrich, Oakville, ON, Canada, unless otherwise indicated.
Cell Cultures
Human PC-3 and DU145 CRPC cells, human LNCaP prostate cancer cells, and mouse TRAMPC2 prostate cancer cells were purchased from the American Type Culture Collection (ATCC); C4-2 CRPC cells were obtained from Dr. Martin E. Gleave, the Vancouver Prostate Centre, Vancouver, BC, Canada. Human monolayer cultures were maintained in RPMI-1640 (GE Healthcare Hyclone, Logan, UT) supplemented with 10% fetal bovine serum (FBS) (GE Healthcare Hyclone, Logan, UT) while TRAMPC2 cells were maintained in DMEM (GE Healthcare Hyclone, Logan, UT) supplemented with 5% FBS. For cell counting, cells were trypsinized to form a single cell suspension and counted using a TC20 Automated Cell Counter (Bio-Rad, Hercules, CA). Cell viability was assessed by trypan blue exclusion.
Human Prostate Cancer Tissue Microarray (TMA) Construction and Immunohistochemistry
TMAs were manually constructed, as previously described (37, 38) , using various Gleason grades- 
ASO Design and Selection
First-generation phosphorothioate-modified ASOs against human MCT4 were rationally designed by selecting sequences containing favourable motifs while excluding unfavourable ones (39) . Specificity of MCT4-targeting sequences, compared to human and mouse genes (at least 3 of 20 bases mismatched), was evaluated using BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Ten sequences (see Table S1 ) 
ASO and siRNA Transfection
Cells were transfected in 6-well plates with ASOs at 100 nM for 48 hours (unless otherwise indicated) using Oligofectamine (Invitrogen, Carlsbad, CA) or with MCT4-targeting siRNAs and controls (Dharmacon, Chicago, IL) at 50 nM for 48 hours using Lipofectamine 2000 (Invitrogen), following the manufacturer's instructions.
Quantitative PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen Inc., Hilden, Germany) and cDNA synthesized using the QuantiTect Reverse Transcription Kit (Qiagen). Primers (see Table S1 ) were designed using Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). qRT-PCR reactions using KAPA SYBR Fast Universal (Kapa Biosystems, Woburn, MA) were performed in triplicate in a ViiA 7 Real-Time PCR system (Applied Biosystems, Foster City, CA). Target genes were normalized to a geometric average of 3 internal reference genes (42) .
Western Blotting
Cells were harvested and lysed in RIPA buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 1% Igepal, 0.5% Nadeoxycholate, 0.1% SDS) supplemented with a complete protease inhibitor cocktail (Roche, Nutley, NJ). Odyssey blocking buffer (Li-cor Biosciences) and probed with anti-MCT4 antibody. Vinculin was used as a loading control. Following overnight incubation at 4°C, the primary antibody was probed with the corresponding secondary antibody and detected using the Odyssey Infrared Imaging System (Li-cor Biosciences) and Image Studio Version 3.1 (Li-cor Biosciences). Densitometry analysis was done using ImageJ (U. S. National Institutes of Health, Bethesda, MD).
Modified Boyden Chamber Assay
The migration and invasion potential of PC-3 cells following treatment with MCT4 ASOs was investigated using Matrigel-coated modified boyden chambers (BD Bioscience, San Jose, CA) as previously described (38) . Briefly, ASO-treated cells were seeded into the top chamber at 50,000 live cells per well. The cells were then resuspended after 48 hours using dissociation buffer (Trevigen, Gaithersburg, MD) containing calcein AMS (12.5 mM; Trevigen). The number of migrated/invaded cells in the lower chamber was determined by fluorescence measurement (485 nm excitation, 520 nm emission) of the cell suspensions using the Infinite F500 fluorometer (Tecan, Männedorf, Switzerland).
Lactate and Glucose Determination
PC-3 cells transfected with ASOs for 48 hours were assessed for lactate and glucose levels. Cells were incubated with fresh media for 4 hours. A sample of the media was then taken and deproteinated with 10K Spin Columns (BioVision, Milpitas, CA) prior to determination of lactate concentration using Lactate Assay Kit (BioVision) and glucose concentration using Glucose Assay Kit (BioVision). Intracellular lactate levels were determined by lysing ASO-transfected cells in MQH 2 O. Final concentrations were determined by normalizing to the total number of live cells.
Treatment with MCT4 ASO of PC-3 Tumor-bearing Nude Mice
Research. , mice were randomized into four groups and treated with intraperitoneal injections of MCT4 ASO #1, #14, control ASO, or vehicle (PBS) at 10 mg/kg daily for 5 days followed by 2 days off treatment for a total of 15 days. The health of the mice was monitored throughout the study by measuring body weights and checking for abnormal behaviour such as lethargy, lack of hydration, and additional signs of weakness. Tumour size was measured twice weekly and tumour volume calculated using the formula: Volume = Length x width x depth x 0.5236 (mm 3 ). Mice were sacrificed 1 hour after the final dose for tissue harvesting.
Immunohistochemistry of Tumour Tissue
Tumour tissue was formalin-fixed and paraffin-embedded for immunohistochemical analysis. Tissues were sectioned, probed, and stained with DAB (Sigma) as previously described (43 
Statistical Analysis
Research. All pooled results are represented as Mean ± SEM. Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA). The Student t-test was carried out to compare means between two groups. One-way ANOVA followed by the post-hoc Dunnett's test was used to compare means of more than two groups. Two-way ANOVA followed by post-hoc multiple comparison was applied to compare tumour growth. A contingency test was done to compare staining intensity between patient cohorts on the tissue microarray. A Log-rank test was done to compare patient survival curves.
Chi-squared tests were done to correlate MCT4 expression levels with various clinical parameters.
Results with a p-value <0.05 were considered statistically significant and are indicated by * for p<0.05, ** for p<0.01, and *** for p<0.001. (Fig. 1C) . Additionally, high MCT4 expression was correlated with other clinical characteristics associated with poor prognosis, such as higher serum PSA levels at diagnosis and clinical T stage (Table S2) . Furthermore, elevated MCT4 protein expression was found in tumours from patients subjected to prolonged neo-adjuvant hormone therapy (>6 months) and CRPC patients ( Figs 1D, E) , indicating that elevated expression of MCT4 protein in prostate cancer is associated with development of CRPC.
Results
Elevated MCT4 Protein Expression is Associated with CRPC
Knockdown of MCT4 Inhibits PC-3 Cell Proliferation
Research. 
The potential therapeutic efficacy of inhibiting MCT4 expression was investigated using MCT4-targeting siRNAs and ASOs. Human PC-3 CRPC cells were used as they present a distinct glycolytic metabolic profile, a property associated with MCT4 expression (20) . As shown in Figure 2A , treatment of PC-3 cells with MCT4 siRNA led to an inhibition of cell proliferation, suggesting potential therapeutic efficacy of an MCT4 knockdown approach. Accordingly, ASOs specifically targeting human MCT4 were designed.
Screening of ten MCT4 ASOs revealed varying capacities of inhibiting PC-3 cell proliferation and MCT4 expression, with ASOs #1 and #14 showing the greatest potency (Figs 2B, 2C) . A strong correlation was found between the reduced levels of MCT4 mRNA in PC-3 cells treated with the various ASOs and the resulting cell numbers (Fig. 2D) , indicating that the growth inhibition by the ASOs was directly related to MCT4 knockdown.
Candidate MCT4 ASOs Inhibit PC-3 Cell Proliferation in a Sustained and Dose-dependent Manner
The growth-inhibitory activities of MCT4 ASOs #1 and #14 were further characterized. As shown in 26nM for ASO #14 (Fig. 3A) . Furthermore, when the ASOs were transfected into human DU145 prostate cancer cells, a similar inhibitory effect on cell proliferation and MCT4 expression was observed with almost identical IC 50 values (Fig. 3B) . Transfection of ASOs into LNCaP prostate cancer cells also showed a similar inhibition of cell proliferation and MCT4 expression (Fig. S1) , suggesting that the inhibitory effect is more associated with a glycolytic phenotype than androgen receptor status. Importantly, transfection of MCT4 ASOs #1 and #14 into mouse TRAMPC2 prostate cancer cells did not lead to a significant reduction in cell proliferation or mouse MCT4 expression (Fig. 3C) . Taken together, the results suggest that these ASOs specifically target human MCT4 and that their inhibitory effect on cell proliferation is a consequence of MCT4 knock-down.
Candidate MCT4 ASOs are able to inhibit glucose metabolism and tissue invasion/migration of CRPC cells in vitro
To further examine the effects of MCT4-targeting ASOs on prostate cancer cells, we measured their effects on lactic acid secretion, intracellular lactate concentrations, and glucose consumption of PC-3 cells. Transfection of the cells with MCT4 ASOs #1 and #14 led to a marked inhibition of lactic acid secretion, a corresponding accumulation of intracellular lactate and an extensive decrease in glucose consumption, measured after 48 hours of transfection (Fig. 4A) . Furthermore, as shown in Figure 4B , treatment with the ASOs resulted in down regulation of various genes involved in glycolysis, i.e. GAPDH, PGK1, PGAM1 and ENO1. In addition, expression of lactate dehydrogenase A (LDHA) was found to be depressed, indicative of a decrease in the conversion of pyruvate to lactic acid. Moreover, decreased expression was found for pyruvate dehydrogenase kinase-1 (PDK1), an enzyme that shunts pyruvate away from the TCA cycle and promotes its conversion to lactic acid. Thus the treatment with the MCT4 ASOs led to inhibition of aerobic glycolysis. Treatment with MCT4 ASOs also inhibited the migration and tissue invasion of PC-3 cells in modified boyden chambers (Fig. S2) , suggesting that lactic acid secretion as facilitated by MCT4 could also play an important role in the metastatic process.
Growth of PC-3 Xenografts in Nude Mice Inhibited by Treatment with MCT4 ASOs
Male athymic nude mice bearing subcutaneous PC-3 tumours were treated with MCT4 ASOs #1 and #14 for a total of 15 days. Both ASOs markedly inhibited the growth of the tumours (Fig. 5A ) without inducing major host toxicity as assessed by monitoring animal weights (Fig. S3) and behaviour.
Immunohistochemical analysis revealed that the ASO-induced inhibition of tumour growth was associated with an increase in cell apoptosis, as measured by cleaved-caspase 3 staining, and a decrease in cell proliferation, as measured by Ki-67 staining (Fig. 5B) . The decrease in tumour growth was associated with a decrease in MCT4 protein expression (Fig. 5C) , consistent with an anti-proliferative effect generated by MCT4 knockdown.
Effects of MCT4 ASOs on Immune Cell Aggregates in Nude Mice
As lactic acid-induced acidification of tumours has been linked to suppression of local host anticancer immunity (14) , it was of interest to determine whether the treatment of the PC-3 tumour-bearing nude mice with MCT4 ASOs had caused changes in the local host immune response of these mice even though their immune reactivity was very limited. To that end, we quantified immune cell aggregates that had extravasated from CD31-positive blood vessels, particularly in the tumour periphery. As shown in Fig.   6A , xenografts treated with the two MCT4 ASOs had significantly larger immune cell aggregates compared to control tumours. Quantification of the natural killer (NK) cell population, the predominant cytotoxic immune cell subtype in nude mice (44) , revealed that the treatment with the MCT4 ASOs markedly increased the proportion of tumour-associated NK cells (Fig. 6B) . Furthermore, activation of with the T-cell receptor complex. Its expression in NK cells is detectable by immunohistochemistry (46) , and in view of the absence of T cells in nude mice, can be used as an indicator of NK cell activation (47) .
As shown in Figure 6C , CD3 staining revealed that the proportion of activated NK cells associated with the ASO-treated tumours had also increased.
Discussion
Cancers have a common preference for reprogrammed energy metabolism leading to upregulated glycolysis and excessive lactic acid secretion, an emerging hallmark of cancer (48); the lactic acid secretion is thought to be predominantly mediated by the MCT4 plasma membrane transporter protein (Table S2 ).
These observations are consistent with reports by others (28, 29), indicating that elevated MCT4 expression is clinically relevant and may play an important role in the late and more aggressive stages of the disease. Thus, stimulation of cancer progression by elevated expression of MCT4 leading to increased lactic acid secretion is consistent with the notion that lactic acid generated by cancers can aid their progression by promoting a variety of oncogenic processes.
Support for potential use of MCT4-targeting ASOs for therapy of CRPC comes from our findings that treatment with MCT4 ASOs #1 and #14 markedly reduced MCT4 mRNA expression (Fig. 2C) , lactic acid secretion and glucose consumption by PC-3 cells (Fig. 4A) Fig. 5A) , which was associated with increased apoptosis (Fig. 5B ) and a reduction in MCT4 protein levels (Fig. 5C ). As well, the treatment with the ASOs did not induce major toxicity to the hosts (Fig. S3) .
The MCT4 ASOs produced in the present study appear to be highly specific for human MCT4, as the specificities of their sequences were checked via BLAST analysis (see Materials and Methods) and as they had highly similar inhibitory effects on the MCT4 expression and proliferation of human PC-3, DU145, C4-2, and LNCaP prostate cancer cells (Figs 2A-F, 3A ,B, and S1) as distinct from mouse TRAMPC2 prostate cancer cells which were not significantly affected by the ASOs (Fig. 3C) . The marked MCT4 ASOinduced inhibition of lactic acid secretion and corresponding increase in intracellular lactic acid concentration are therefore likely a direct result of MCT4 knockdown (Fig. 4A) . The ASO-induced inhibition of glucose consumption (Fig. 4A ) and down-regulation of enzymes involved in aerobic glycolysis (Fig. 4B ) appear to be secondary effects, probably reflecting a response of the cancer cells to reduce the potentially fatal increase in intracellular lactic acid content by shutting off the lactic acid supply. Furthermore, decreasing MCT4 expression also resulted in the reduction of Matrigel invasion and in vitro migration of PC-3 cells (Fig. S2) , lending preliminary confirmation that lactic acid secretion may play an important role in local tissue invasion and metastasis (15, 16) . Elucidation of the precise mechanisms by which down regulation of MCT4 inhibits proliferation, tissue invasion and migration of prostate cancer cells, and other aspects of cancer biology such as tumorigenesis, requires further studies. In particular, FDG-PET could be used as a metabolic tracer to determine whether glucose uptake by prostate cancer cells in vivo is affected by treatment with MCT4 ASOs. Alternatively, metabolomic approaches using stable isotope-labelled metabolites such as (Fig. 6A) , ii) the proportions of host NK cells (Fig. 6B) and iii) the proportions of host NK cells that had been activated (Fig. 6C) . They indicate that MCT4 knockdown might lead to restoration of cancer-suppressed host immunity, a possibility that should be examined using immuno-competent hosts.
Elevated MCT4 expression has also been reported as clinically relevant and functionally significant in other types of cancer (25, 27) . For example, MCT4-targeting siRNA has been reported to be effective at inhibiting renal cell carcinoma growth (51) , and MCT4 expression in small cell lung cancer was found to confer resistance to specific MCT1 inhibitors (32) . The candidate MCT4 ASOs developed in our laboratory could therefore be useful in multiple clinical settings, in particular if their efficacies can be improved by incorporating second-generation 2'-methoxyethyl modifications in their backbone (52) .
Additionally, treatment efficacy could also be increased using a combination strategy with other The decrease in cell proliferation is associated with a decrease in MCT4 expression. Taken together, the data suggest that the inhibitory effect of MCT4 ASOs may be more associated with a glycolytic phenotype than with androgen receptor status. 
